|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM257174893 |
| 003 |
DE-627 |
| 005 |
20231224182236.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2015.12.009
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0857.xml
|
| 035 |
|
|
|a (DE-627)NLM257174893
|
| 035 |
|
|
|a (NLM)26845678
|
| 035 |
|
|
|a (PII)S1521-6616(15)30078-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Liu, Xiao-Fang
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.07.2016
|
| 500 |
|
|
|a Date Revised 07.03.2016
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2016 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a MiR-15a is likely to be associated with autoimmunity. Here, we aimed to examine the expression of miR-15 cluster in PBMCs from myasthenia gravis (MG) patients and investigate the potential roles of miR-15a in MG. We found that the expression of all miR-15 cluster was decreased in MG, furthermore, miR-15a levels in ocular MG (oMG) were much lower, while CXCL10 production was increased in MG. We display that CXCL10 was a functional target gene of miR-15a in MG. Increasing miR-15a expression could reduce CXCL10 expression and alleviate the abnormal T cells activation in immune response, while decreasing miR-15a expression could activate immune response abnormally. Moreover, miR-15a expression was significantly decreased after stimulation, and prednisone treatment could upregulate miR-15a expression in steroid-responsive MG patients. Take together, our data suggest that decreased miR-15a expression facilitates proinflammatory cytokines production and contributes to immune response at least in part via regulating CXCL10 expression in MG
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a CXCL10
|
| 650 |
|
4 |
|a Immune response, T cells
|
| 650 |
|
4 |
|a Myasthenia gravis
|
| 650 |
|
4 |
|a miR-15a
|
| 650 |
|
7 |
|a CXCL10 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Chemokine CXCL10
|2 NLM
|
| 650 |
|
7 |
|a MIRN15 microRNA, human
|2 NLM
|
| 650 |
|
7 |
|a MicroRNAs
|2 NLM
|
| 700 |
1 |
|
|a Wang, Run-Qi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hu, Bo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luo, Meng-Chuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zeng, Qiu-Ming
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Hao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Kun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dong, Xiao-Hua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luo, Yue-Bei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luo, Zhao-Hui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Huan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 164(2016) vom: 07. März, Seite 106-13
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:164
|g year:2016
|g day:07
|g month:03
|g pages:106-13
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2015.12.009
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 164
|j 2016
|b 07
|c 03
|h 106-13
|